PROTEIN TOXINS ACTIVE AGAINST LEPIDOPTERAN PESTS

Abstract: Disclosed and claimed are novel Bacillus thuringiensis isolates which have lepidopteran activity. Thus, these isolates, or mutants thereof, can be used to control such insect pests. Further, genes encoding novel delta -endotoxins can be removed from the isolates and transferred to other host microbes, or plants. Expression of the delta -endotoxins in such hosts results in the control of susceptible insect pests in the environment of such hosts.

Description: DESCRIPTION 0R-1 ON ORPHAN RECEPTOR BEL0NGIN6 TO THE NUCLEAR RECEPTOR FAMILY Cross-Reference to a Related Application This is a continuation-in-part of co-pending application Serial No.08/032,778, filed March 16, 1993, which is a continuation of application Serial No.07/597,607, filed October 15, 1990, now abandoned. Background of the Invention The soil microbe Bacillus thuringiensis (B.t.) is a Gram-positive, spore-forming bacterium characterized by parasporal crystalline protein inclusions. These inclusions often appear microscopically as distinctively shaped crystals. These crystalline proteins can be profoπns of ό- endo toxins which are highly toxic to pests and specific in their toxic activity. Certain B. endotoxin genes have been isolated and sequenced, and recombinant DNA-based B.t products have been produced and approved. In addition, with the use of genetic engineering techniques, new approaches for delivering B.t endotoxins to agricultural environments are under development, including the use of plants genetically engineered with endotoxin genes for insect resistance and the use of stabilized intact microbial cells as B.t. endotoxin delivery vehicles (Gaertner, F.H., L. Kim [1988] TIBTECH 6:S4-S7). Thus, isolated B.t. endotoxin genes are becoming commercially valuable. Until the last ten years, commercial use of _B.r. pesticides has been largely restricted to a narrow range of lepidopteran (caterpillar) pests. Preparations of the spores and crystals of .9. thuringiensis subsp. kurstaki have been used for many years as commercial insecticides for lepidopteran pests. For example, B. thuringiensis var. kurstaki HD-1 produces a delta endotoxin which is toxic to the larvae of a number of lepidopteran insects. In recent years, however, investigators have discovered B.t. pesticides with specificities for a much broader range of pests. For example, subspecies of B.t, namely israelensis and son diego (a.k.a. B.t tenebrionis, a.k.a. M-7), have been used commercially to control insects of the orders Diptera and Coleoptera, respectively (Gaertner, F.H. [1989] "Cellular Delivery Systems for Insecticidal Proteins: Living and Non-living Microorganisms," in Controlled Delivery of Crop Protection Agents, R.M. Wilkins, ed., Taylor and Francis, New York and London, 1990, pp. 245- 255). See also Couch, T.L. (1980) "Mosquito Pathogenicity of Bacillus thuringiensis var. israelensis " Developments in Industrial Microbiology 22:61-76; Beegle, C.C., (1978) "Use of Entomogenous Bacteria in Agroecosystems," Developments in Industrial Microbiology 20:97-104. Krieg, A., A.M. Huger, G.A. Langenbruch, W. Schnetter (1983) Z ang. Ent 96:500-508, describe a B.t. isolate named Bacillus thuringiensis var. tenebrionis, which is reportedly active against two beetles in the order Coleoptera. These are the Colorado potato beetle, Leptinotarsa decemlineata, and Agelastica alni. Recently, new subspecies of B.t have been identified, and genes responsible for active ό- endotoxin proteins have been isolated (Hofte, H., H.R. Whiteley [1989] Microbiological Reviews 52(2):242-255). Hofte and Whiteley classified B.t crystal protein genes into 4 major classes. The classes were Cryl (Lepidoptera-specific), Cryll (Lepidoptera- and Diptera-specific), Crylll (Coleoptera-specific), and CrylV (Diptera-specific). The discovery of strains specifically toxic to other pests has been reported. (Feitelson, J.S., J. Payne, L. Kim [1992] Bio/Technology 10:271-275). The cloning and expression of a B.t. crystal protein gene in Escherichia coli has been described in the published literature (Schnepf, H.E., H.R. Whiteley [1981] Proc. NatL Acad. Sci. USA 78:2893-2897). U.S. Patent 4,448,885 and U.S. Patent 4,467,036 both disclose the expression of B.t. crystal protein in E. coli. U.S. Patents 4,797,276 and 4,853331 disclose B. thuringiensis var. san diego (a.k.a. B.t tenebrionis, a.k.a. M-7) which can be used to control coleopteran pests in various environments. U.S. Patent No. 5,164,180 discloses a B.t isolate, PS81A2, which is artive against lepidopteran pests. U.S. Patent No. 5,151,363 discloses certain isolates of B.t which have activity against nematodes. Many other patents have issued for new B.t. isolates and new uses of B.t isolates. The discovery of new B.t. isolates and new uses of known B.t. isolates remains an empirical, unpredictable art. Brief Summary of the Invention The subject invention concerns novel Bacillus thuringiensis isolates which have activity against lepidopteran pests. Specifically, the invention comprises novel B.t isolates and mutants thereof, and novel delta endotoxin genes obtainable from these B.t. isolates which encode proteins which are active against lepidopteran pests. Brief Description of the Drawing Figure 1 shows the one-letter amino acid sequence of the Generic Formula (SEQ ID NO. 27). Numbering is for convenience and approximate location only. In the Generic Formula, the N-terminal half of the molecule is comprised of residue nos. 1-638. The C-terminal half is comprised of residues 639-1213. Wherein A - ala G = gly M = met S = ser C = cys H = his N = asn T = thr D — asp I = ile P = pro V = val E = glu K = lys Q = gln W = trp F = phe L = leu R = arg Y =tyr k = K or R z = G, S, D, or N j = E, Q, R, or K x = G, S, D, N, E, Q, R, or K u = C, P, T, or A b = M, I, L, V, or F o = C, P, T, A, M, I, L, V, or F - = any naturally occurring amino acid . = any naturally occurring amino acid or complete omission thereof. Brief Description of the Sequences SEQ ID NO. 1 is the nucleotide sequence of the gene 81A2. SEQ ID NO. 2 is the amino acid sequence of the toxin 81A2. SEQ ID NO. 3 is the nucleotide sequence of the gene 91C2. SEQ ID NO. 4 is the amino acid sequence of the toxin 91 C2. SEQ ID NO.5 is a radiolabeled oligonucleotide probe used in RFLP analysis as described in Example 3. SEQ ID NO.6 is a forward oligonucleotide primer used to amplify gene 91 C2 according to the subject invention. SEQ ID NO. 7 is a reverse oligonucleotide primer used to amplify gene 91 C2 according to the subject invention. SEQ ID NO. 8 is a synthetic oligonucleotide probe used to identify gene 91C2 according to the subject invention. SEQ ID NO. 9 is the peptide sequence encoded by probes for CrylF genes. SEQ LD NO. 10 is a nucleotide probe according to the subject invention. SEQ ID NO. 11 is the peptide sequence encoded by probes for CrylF genes. SEQ LD NO. 12 is a nucleotide probe according to the subject invention. SEQ LD NO. 13 is the peptide sequence encoded by probes for CrylF genes. SEQ LD NO. 14 is a nucleotide probe according to the subject invention. SEQ ID NO. 15 is the peptide sequence encoded by probes for CrylF genes. SEQ ID NO. 16 is a nucleotide probe according to the subject invention. SEQ DD NO. 17 is the peptide sequence encoded by probes for CrylF genes. SEQ ID NO. 18 is a nucleotide probe according to the subject invention. SEQ ID NO. 19 is the peptide sequence encoded by probes for CrylF genes. SEQ LD NO. 20 is a nucleotide probe according to the subject invention. SEQ ID NO. 21 is the peptide sequence encoded by probes for CrylF genes. SEQ ID NO. 22 is a nucleotide probe according to the subject invention. SEQ ID NO. 23 is the peptide sequence encoded by probes for CrylF genes. SEQ ED NO. 24 is a nucleotide probe according to the subject invention. SEQ LO NO. 25 is the peptide sequence encoded by probes for CrylF genes. SEQ ID NO. 26 is a nucleotide probe according to the subject invention. SEQ ID NO. 27 is the Generic Formula according to the subject invention. Detailed Disclosure of the Invention The subject invention concerns isolates of Bacillus thuringiensis having anti-lepidopteran activity. These isolates comprise genes which code for ό-endotoxins, which toxins are responsible for the observed anti-lepidopteran activity. Thus, the subject invention concerns anti-lepidopteran B.t. isolates, anti-lepidopteran B.t toxins, and genes which encode these toxins. Further embodiments of the subject invention concern recombinant hosts transformed with genes encoding the anti-lepidopteran B.t toxins. The subject invention further concerns methods for controlling lepidopterans, said methods comprising the use of the isolates, toxins, genes, and recombinant hosts of the subject invention. Specifically exemplified herein are the isolates designated B.t PS81T1, B.t PS53C2, B.t PS31F4, B.t PS86V1, B.t PS 8612, B.t PS73E, B.t PS81K, B.t PS83E2, B.t. PS81E, B.t PS81Z3, B.t PS53B5, B.t PS83R, B.t. PS53B2, B.t PS83N2, B.t. PS81B5, B.t PS86W1, and B.t PS93C2. Also specifically exemplified is the toxin designated 91 C2 and the gene which encodes this toxin. The 91C2 gene is a CryEF gene. CrylF is a subclass of genes within the lepidopteran-active Cryl class of B.t genes. The discovery described in the subject application enables a person skilled in the an to identify other CrylF toxins (and genes coding for these toxins) having anti-lepidopteran activity. The toxins of the subject invention are characterized as being active against lepidopterans and having one or more of the following characteristics: 1. A high degree of amino acid homology with toxin 91 C2. 2. A nucleotide sequence encoding the toxin wherein the nucleotide sequence hybridizes with probes or genes disclosed herein. 3. A nucleotide sequence encoding the toxin wherein the nucleotide sequence can be amplified by PCR using primers disclosed herein. 4. An amino acid sequence which conforms to the Generic Formula presented herein. 5. Immunoreactivity to an antibody raised to toxin 91C2. Bacillus thuringiensis isolates useful according to the subject invention have the following characteristics in their biologically pure form: Table 1. Taxonomic characterization of the B.t. isolates of the subject invention Approx. Toxin Isolate Crystal Type MW (kD) Serotype Activity PS81T1 bipyramid 130 aizawai Lepidoptera PS53C2 bipyramid 130, 60 kurstaki Lepidoptera PS31F4 bipyramid 130, 60 kurstaki Lepidoptera PS86V1 bipyramid 130 galleriae Lepidoptera PS86I2 bipyramid 130 morrisoni Lepidoptera PS73E bipyramid 130 aizawai Lepidoptera PS81K bipyramid 130 aizawai Lepidoptera PS83E2 amorphic 130 aizawai Lepidoptera PS81E bipyramid 130 aizawai Lepidoptera PS81Z3 bipyramid 130 aizawai Lepidoptera PS53B5 bipyramid 130, 60 kenyae Lepidoptera PS83R bipyramid 130 aizawai Lepidoptera PS53B2 bipyramid 130, 60 kenyae Lepidoptera PS83N2 bipyramid 130, 60 sotto/kenyae Lepidoptera PS81B5 amorphic 130 aizawai " Lepidoptera PS86W1 bipyramid 130 galleriae Lepidoptera PS91C2 bipyramid 130 morrisoni Lepidoptera B.t isolates useful according to the subject invention have been deposited. Also deposited are recombinant microbes comprising the B.t. genes of interest. The cultures have been deposited in the permanent collection of the Patent Culture Collection (NRRL), Regional Research Center, 1815 North University Street, Peoria, Illinois 61604 USA Culture Accession Number Deposit Date Bacillus thuringiensis PS81IA NRRL B-18484 April 19, 1989 Bacillus thuringiensis PS91C2 NRRL B-18931 December 27, 1991 E. coli NM522 (pMYC2361) NRRL B-21016N December 17, 1992 The subject cultures have been deposited under conditions that assure that access to the cultures will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 CFR 1.14 and 35 U.S.C. §122. The deposits are available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny, are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action. Further, the subject culture deposits will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of Microorganisms, i.e., they will be stored with all the care necessary to keep them viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposit, and in any case, for a period of at least 30 (thirty) years after the date of deposit or for the enforceable life of any patent which may issue disclosing the cultures. The depositor acknowledges the duty to replace the deposits should the depository be unable to furnish a sample when requested, due to the condition of the deposit(s). All restrictions on the availability to the public of the subject culture deposits will be irrevocably removed upon the granting of a patent disclosing them. Toxins and genes. The toxins and genes according to the subject invention include not only the full length sequences disclosed herein but also fragments of these sequences, longer sequences, and fusion proteins, which retain the characteristic pesticidal activity of the toxins specifically exemplified herein. One aspect of the subject invention concerns the discovery of a generic chemical formula hereinafter referred to as the Generic Formula (SEQ ED NO. 27), which can be used to identify toxins having activity against lepidopterans. The Generic Formula describes toxin proteins having molecular weights of about 130 kDa. The Generic Formula is shown in Figure 1 designated by a one-letter amino acid sequence. The Sequence Listing provided herein according to the Patentln format utilizes the three-letter amino acid code and has no provision for showing a choice between two amino acids at a given position. Therefore, within the Patentln Sequence Listing, "Xaa" is used to denote points of variation within a sequence, but the single letter code of Figure 1 should be referred to for the specific amino acid substitutions which are acceptable at a given location in the sequence. Further guidance for characterizing the lepidopteran toxins of the subject invention is provided in Tables 2 and 3, which demonstrate the relatedness among toxins within the known Cryl subclasses of lepidopteran toxins. These tables show a numeric score for the best matching alignment between two proteins that reflects: (1) positive scores for exact matches, (2) positive or negative scores reflecting the likelihood (or not) of one amino acid substituting for another in a related protein, and (3) negative scores for the introduction of gaps. A protein sequence aligned to itself will have the highest possible score, i.e., all exact matches and no gaps. However, an unrelated protein or a randomly generated sequence will typically have a low positive score. Related sequences have scores between the random background score and the perfect match score. The sequence comparisons reported herein were made using the algorithm of Smith and Waterman ([1981] Advances in Applied Mathematics 2:482-489), implemented as the program "Bestfit" in the GCG Sequence Analysis Software Package Version 7, April 1991. The sequences were compared with default parameter values (comparison: Swagappep.Cmp, Gap: 3.0, length weight: 0.1). The program output value is referred to as the Quality score. Tables 2 and 3 show the pairwise alignment scores between the indicated amino acids of the Cryl toxin proteins. Table 4 shows the amino acids compared from the proteins of interest. Table 2 shows the scores prior to adjustment for random sequence scores. Note that for each subclass, the highest alignment score is always with another toxin protein from the same subclass. For example, the highest alignment score with CryΙA(a), aside from itself, is with CryΙA(d). Furthermore, CryLA(a) scores highest with all three other CryLA toxin proteins. In a similar manner, other Cryl toxins score highest with other members of the same subclass. Of particular relevance to the subject invention is the fact that the CrylF toxin proteins score highest with each other. Table 3 shows the same analysis after subtraction of the average score of 50 alignments of random shuffles of the column sequences with the row sequences. Note that in Table 3 the same relationships hold as in Table 2, i.e., toxin proteins score highest with other members of the same subclass. Again, the two CrylF toxin proteins score highest with each other. Examination of the adjusted alignment scores for members of the same subclass reveals that Cryl subclasses can be defined as those proteins with adjusted alignment scores of about 450 or greater. Thus, certain toxins of the subject invention can be defined as those which have lepidopteran activity and have an alignment value of 450-500 or greater with CryΙF(a) or CryIF(b) (91C2). As used herein, the term "alignment value" refers to the adjusted scores obtained above and used to create the scores reported in Table 3. Table 4. Protein Amino acids compared CryΙA(a) 1-607 CryIA(b) 1-608 CryIA(c) 1-609 CryΙA(d) 1-607 CrylB 1-636 CrylC 1-617 CryED 1-592 CryΙE(a) 1-601 CryIE(b) 1-599 CryIF(a) 1-601 CryIF(b) (91C2) 1-600 Toxins of the subject invention are specifically exemplified herein by the toxin encoded by the gene designated 91C2. Since this toxin is merely exemplary of the toxins of the subjert invention, it should be readily apparent that the subject invention further comprises variant toxins (and nucleotide sequences coding for variant toxins) having the same, or essentially the same, biological activity against lepidopterans of 91C2. These equivalent toxins will have amino acid homology with 91 C2. This amino acid homology will typically be greater than 75%, preferably be greater than 90%, and most preferably be greater than 95%. The amino acid homology will be highest in certain critical regions of the toxin which account for biological activity or are involved in the determination of three-dimensional configuration which ultimately is responsible for the biological activity. In this regard, certain amino acid substitutions are acceptable and can be readily made in regions which are not critical to activity or are conservative amino acid substitutions which do not affect the three-dimensional configuration of the molecule. For example, amino acids may be placed in the following classes: non-polar, uncharged polar, basic, and acidic. Conservative substitutions whereby an amino acid of one class is replaced with another amino acid of the same type fall within the scope of the subjert invention so long as the substitution does not materially alter the biological activity of the compound. Table 5 provides a listing of examples of amino acids belonging to each class. Table 5 Class of Amino Acid Examples of Amino Acids Nonpolar Ala, Val, Leu, He, Pro, Met, Phe, Trp Uncharged Polar Gly, Ser, Thr, Cys, Tyr, Asn, Gin Acidic Asp, Glu Basic Lys, Arg, His In some instances, non-conservative substitutions can also be made. The critical factor is that these substitutions must not significantly detract from the biological activity of the toxin. The toxins of the subject invention can also be characterized in terms of the shape and location of toxin inclusions, which are described above. It should be apparent to a person skilled in this art that genes encoding lepidopteran- active toxins can be identified and obtained through several means. The specific genes exemplified herein may be obtained from the isolates deposited at a culture depository as described above. These genes, or portions or variants thereof, may also be constructed synthetically, for example, by use of a gene machine. As used herein, the terms "variants" or "variations" of genes refer to nucleotide sequences which code for the same toxins or which code for equivalent toxins having lepidopteran activity. Variations of these genes may be readily constructed using standard techniques for making point mutations. Also, fragments of these genes can be made using commercially available exonucleases or endonucleases according to standard procedures. For example, enzymes such as Ba l or site-direrted mutagenesis can be used to systematically cut off nucleotides from the ends of these genes. Also, genes which code for active fragments may be obtained using a variety of other restriction enzymes. Proteases may be used to directly obtain active fragments of these toxins. Equivalent toxins and/or genes encoding these equivalent toxins can also be located from B.t. isolates and/or DNA libraries using the teachings provided herein. There are a number of methods for obtaining the pesticidal toxins of the instant invention. For example, antibodies to the pesticidal toxins disclosed and claimed herein can be used to identify and isolate other toxins from a mixture of proteins. Specifically, antibodies may be raised to the portions of the toxins which are most constant and most distinct from other B.t toxins. These antibodies can then be used to specifically identify equivalent toxins with the characteristic activity by immunoprecipitation, enzyme linked immunosorbent assay (ELISA), or Western blotting. Antibodies to the toxins disclosed herein, or to equivalent toxins, or fragments of these toxins, can readily be prepared using standard procedures in this art. The genes coding for these toxins can then be obtained from the microorganism. A further method for identifying the toxins and genes of the subjert invention is through the use of oligonucleotide probes. These probes are detectable nucleotide sequences. These sequences may be detectable by virtue of an appropriate label or may be made inherently fluorescent as described in International Patent Application No. WO93/16094. As is well known in the art, if the probe molecule and nucleic acid sample hybridize by forming a strong bond between the two molecules, it can be reasonably assumed that the probe and sample have substantial homology. Detection of the probe provides a means for determining in a known manner whether hybridization has occurred. Such a probe analysis provides a rapid method for identifying toxin-encoding genes of the subjert invention. The nucleotide segments which are used as probes according to the invention can be synthesized by use of DNA synthesizers using standard procedures. In the use of labeled nucleotide segments as probes, the particular probe is labeled with any suitable label known to those skilled in the art, including radioactive and non-radioactive labels. Typical radioactive labels include 32 P, 125 I, 35 S, or the like. A probe labeled with a radioactive isotope can be constructed from a nucleotide sequence complementary to the DNA sample by a conventional nick translation reaction, using a DNase and DNA polymerase. The probe and sample can then be combined in a hybridization buffer solution and held at an appropriate temperature until annealing occurs. Preferably, hybridization is conducted under stringent conditions by techniques well known in the art, as described, for example, in Keller, G.H., M.M. Manak (1989) DNA Probes, Stockton Press, New York, NY, pp. 169-170. Thereafter, the membrane is washed free of extraneous materials, leaving the sample and bound probe molecules typically detected and quantified by autoradiography and/or liquid scintillation counting. Non-radioactive labels include, for example, ligands such as biotin or thyroxine, as well as enzymes such as hydrolases or perixodases, or the various cherniluminescers such as luciferin, or fluorescent compounds like fluorescein and its derivatives. The probe may also be labeled at both ends with different types of labels for ease of separation, as, for example, by using an isotopic label at the end mentioned above and a biotin label at the other end. Duplex formation and stability depend on substantial complementarity between the two strands of a hybrid; a certain degree of mismatch can be tolerated. Therefore, the probes of the subject invention include mutations (both single and multiple), deletions, insertions of the described sequences, and combinations thereof, wherein said mutations, insertions and deletions permit formation of stable hybrids with the target polynucleotide of interest. Mutations, insertions, and deletions can be produced in a given polynucleotide sequence in many ways, and these methods are known to an ordinarily skilled artisan. Other methods may become known in the future. The known methods include, but are not limited to: (1) synthesizing chemically or otherwise an artificial sequence which is a mutation, insertion or deletion of the known sequence; (2) using a probe of the present invention to obtain via hybridization a new sequence or a mutation, insertion or deletion of the probe sequence; and (3) mutating, inserting or deleting a test sequence in vitro or in vivo. It is important to note that the mutational, insertional, and deletional variants generated from a given probe may be more or less efficient than the original probe. Notwithstanding such differences in efficiency, these variants are within the scope of the present invention. Thus, mutational, insertional, and deletional variants of the disclosed sequences can be readily prepared by methods which are well known to those skilled in the art. These variants can be used in the same manner as the instant probes so long as the variants have substantial sequence homology with the probes. As used herein, substantial sequence homology refers to homology which is sufficient to enable the variant to function in the same capacity as the original probe. Preferably, this homology is greater than 50%; more preferably, this homology is greater than 75%; and most preferably, this homology is greater than 90%. The degree of homology needed for the variant to function in its intended capacity will depend upon the intended use of the sequence. It is well within the skill of a person trained in this art to make mutational, insertional, and deletional mutations which are designed to improve the function of the sequence or otherwise provide a methodological advantage. Specific nucleotide probes useful according to the subject invention in the rapid identification of CrylF class toxin genes include: (i) DNA coding for a peptide sequence "Ser Thr Gly Arg Leu Pro Leu Asp" (SEQ ID NO. 9). A specific example of such a probe is "AGTACWGGMA GRTTACCRTT RGAY" (SEQ ID NO. 10); (ϋ) DNA coding for a peptide sequence "Glu Asp Ser Pro Val Ser Ala Asn" (SEQ ID NO. 11). A specific example of such a probe is "GARGATTCWC CAGTWTCWGC WAAT' (SEQ ID NO. 12); (ϋi) DNA coding for a peptide sequence "Asn Gly Phe Asn Arg Ala Glu Phe Gly Val" (SEQ ID NO. 13). A specific example of such a probe is " AATGGWTTTA ATAGTGCTGA ATTTGGGAGT W" (SEQ ID NO. 14); (iv) DNA coding for a peptide sequence "Val Thr Ala Glu Thr Val Arg Ser Gin Thr" (SEQ ID NO. 15). A specific example of such a probe is "GTAACWGCAG ARACWGTWAG WAGTCAAACW" (SEQ ID NO. 16); (v) DNA coding for a peptide sequence "Val Phe Asn Pro Gly Gly Ala lie Trp lie Ala Asp Glu" (SEQ ED NO. 17). A specific example of such a probe is "GTMTTYAATC CWGGWGGMGC MATWTGGATW GCWGATGARG AT' (SEQ ID NO. 18); (vi) DNA coding for a peptide sequence "Val Arg Gly Gly Phe Gly" (SEQ ID NO. 19). A specific example of such a probe is "GTMMGAGGWG GWTTTGGR" (SEQ ED NO. 20); (vii) DNA coding for a peptide sequence "Gly Thr Asn His Thr Arg Thr" (SEQ ID NO. 21). A specific example of such a probe is "GGWACRAAYC AYACMMGAAC W" (SEQ ID NO. 22); (vϋi) DNA coding for a peptide sequence "Val Arg Trp Pro Gly Glu De" (SEQ ID NO. 23). A specific example of such a probe is "GTWMGATGGC CWGGWGARAT W" (SEQ ID NO. 24); (ix) DNA coding for a peptide sequence "Ser Asp Ser Trp Arg Ala" (SEQ ID NO. 25). A specific example of such a probe is "AGTGATTCWT GGAGAGCW" (SEQ ID NO. 26). Because of the redundancy of the genetic code, i.e., more than one coding nucleotide triplet (codon) can be used for most of the amino acids used to make proteins, different nucleotide sequences can code for a particular amino acid. Thus, the amino acid sequences of the B.t toxins and peptides can be prepared by equivalent nucleotide sequences encoding the same amino acid sequence of the protein or peptide. Accordingly, the subject invention includes such equivalent nucleotide sequences. Also, inverse or complement sequences are an aspect of the subject invention and can be readily used by a person skilled in this art. Recombinant hosts. The toxin-encoding genes harbored by the isolates of the subjert invention can be introduced into a wide variety of microbial or plant hosts. Expression of the toxin gene results, directly or indirectly, in the intracellular production and maintenance of the pesticide. With suitable microbial hosts, e.g., Pseudomonas, live microbes can be applied to the situs of lepidopterans where they will proliferate and be ingested by the pest. The result is a control of this pest. Alternatively, the microbe hosting the toxin gene can be treated under conditions that prolong the activity of the toxin and stabilize the cell. The treated cell, which retains the toxic activity, then can be applied to the environment of the target pesL Where the B.t. toxin gene is introduced via a suitable vector into a microbial host, and said host is applied to the environment in a living state, it is essential that certain host microbes be used. For example, microorganism hosts can be selected which are known to occupy the soil. These microorganisms are selected so as to be capable of successfully competing in the soil with the wild-type microorganisms. It is also important that they provide for stable maintenance and expression of the gene expressing the polypeptide pesticide, and, desirably, provide for improved protection of the pesticide from environmental degradation and inactivation. 96/05314 15 A large number of microorganisms are known to inhabit the rhizosphere (the soil surrounding plant roots). These microorganisms include bacteria, algae, and fungi. Of particular interest are microorganisms, such as bacteria, e.g., genera Bacillus, Pseudomonas, Erwinia, Serratia, Klebsiella, Xanthomonas, Streptomyces, Rhizobium, Rhodopseudomonas, Methylophilius, Agrobacterium, Acetobacter, Lactobacillus, Arthrobacter, Azotobacter, Leuconostoc, Alcaligenes and Clostridium; fungi, particularly yeast, e.g., genera Saccharomyces, Cryptococcus, Kluyveromyces, Sporobolomyces, Rhodotorula, and Aureobasidium; microalgae, e.g., families Cyanophyceae, Prochlorophyceae, Rhodophyceae, Dinophyceae, Chrysophyceae, Prymnesiophyceae, Xanthophyceae, Raphidophyceae, Bacillariophyceae, Eustigmatophyceae, Cryptophyceae, Euglenophyceae, Prasinophyceae, and Chlorophyceae. Of particular interest are such phytosphere bacterial species as Pseudomonas syringae, Pseudomonas fluorescens, Serratia marcescens, Acetobacter xylinum, Agrobacterium tumefaciens, Rhodopseudomonas spheroides, Xanthomonas campestris, Rhizobium melioti, Alcaligenes entrophus, and Azotobacter vinlandii; and phytosphere yeast species such as Rhodotorula rubra, R. glutinis, R. marina, R. aurantiaca, Cryptococcus albidus, C. diffluens, C. laurentii, Saccharomyces rosei, S. pretoriensis, S. cerevisiae, Sporobolomyces roseus, S. odorus, Kluyveromyces veronae, and Aureobasidium pollulans. Of particular interest are the pigmented microorganisms. A wide variety of ways are available for introducing a B.t. gene encoding a toxin into a microorganism host under conditions which allow for stable maintenance and expression of the gene. These methods are well known to those skilled in the art and are described, for example, in United States Patent No. 5,135,867, which is incorporated herein by reference. Treatment of cells. As mentioned above, B.t. or recombinant cells expressing a B.t toxin can be treated to prolong the toxin activity and stabilize the cell. The pesticide microcapsule that is formed comprises the B.t. toxin within a cellular structure that has been stabilized and will protect the toxin when the microcapsule is applied to the environment of the target pest. Suitable host cells may include either prokaryotes or eukaryotes, normally being limited to those cells which do not produce substances toxic to higher organisms, such as mammals. However, organisms which produce substances toxic to higher organisms could be used, where the toxic substances are unstable or the level of application sufficiently low as to avoid any possibility of toxicity to a mammalian host. As hosts, of particular interest will be the prokaryotes and the lower eukaryotes, such as fungi. The cell will usually be intact and be substantially in the proliferative form when treated, rather than in a spore form, although in some instances spores may be employed. Treatment of the microbial cell, e.g., a microbe containing the B.t toxin gene, can be by chemical or physical means, or by a combination of chemical and/or physical means, so long as the technique does not deleteriously affect the properties of the toxin, nor diminish the cellular capability of protecting the toxin. Examples of chemical reagents are halogenating agents, particularly halogens of atomic no. 17-80. More particularly, iodine can be used under mild conditions and for sufficient time to achieve the desired results. Other suitable techniques include treatment with aldehydes, such as formaldehyde and glutaraldehyde; anti-infertives, such as zephiran chloride and cetylpyridinium chloride; alcohols, such as isopropyl and ethanol; various histologic fixatives, such as Lugol iodine, Bouin's fixative, and Helly's fixative (See: Humason, Gretchen L., Animal Tissue Techniques, W.H. Freeman and Company, 1967); or a combination of physical (heat) and chemical agents that preserve and prolong the activity of the toxin produced in the cell when the cell is administered to the host's environment. In one preferred embodiment, acids can be used to stabilize the cells. Examples of physical means are short wavelength radiation such as gamma-radiation and X-radiation, freezing, UV irradiation, lyophilization, and the like. Methods for treatment of microbial cells are disclosed in United States Patent Nos.4,695,455 and 4,695,462, which are incorporated herein by reference. The cells generally will have enhanced structural stability which will enhance resistance to environmental conditions. Where the pesticide is in a profoπn, the method of cell treatment should be selected so as not to inhibit processing of the proform to the mature form of the pesticide by the target pest pathogen. For example, formaldehyde will crosslink proteins and could inhibit processing of the proform of a polypeptide pesticide. The method of treatment should retain a substantial portion of the bio-availability or bioartivity of the toxin. Characteristics of particular interest in selecting a host cell for purposes of production include ease of introducing the B.t gene into the host, availability of expression systems, efficiency of expression, stability of the pesticide in the host, and the presence of auxiliary genetic capabilities. Characteristics of interest for use as a pesticide microcapsule include protective qualities for the pesticide, such as thick cell walls, pigmentation, and intracellular packaging or formation of inclusion bodies; survival in aqueous environments; lack of mammalian toxicity; attractiveness to pests for ingestion; ease of killing and fixing without damage to the toxin; and the like. Other considerations include ease of formulation and handling, economics, storage stability, and the like. Growth of cells. The cellular host containing the B.t insecticidal gene may be grown in any convenient nutrient medium, where the DNA construct provides a selective advantage, providing for a selective medium so that substantially all or all of the cells retain the B.t gene. These cells may then be harvested in accordance with conventional ways. Alternatively, the cells can be treated prior to harvesting. The J9.r. cells of the invention can be cultured using standard art media and fermentation techniques. Upon completion of the fermentation cycle the bacteria can be harvested by first separating the B.t spores and crystals from the fermentation broth by means well known in the art. The recovered B.t spores and crystals can be formulated into a wettable powder, liquid concentrate, granules or other formulations by the addition of surfactants, dispersants, inert carriers, and other components to facilitate handling and application for particular target pests. These formulations and application procedures are all well known in the art. Formulations. Formulated bait granules containing an attractant and spores and crystals of the B.t isolates, or recombinant microbes comprising the gene(s) obtainable from the B.t isolates disclosed herein, can be applied to the soil. Formulated product can also be applied as a seed-coating or root treatment or total plant treatment at later stages of the crop cycle. As would be appreciated by a person skilled in the art, the pesticidal concentration will vary widely depending upon the nature of the particular formulation, particularly whether it is a concentrate or to be used directly. The pesticide will be present in at least 1% by weight and may be 100% by weight. The dry formulations will have from about 1-95% by weight of the pesticide while the liquid formulations will generally be from about 1-60% by weight of the solids in the liquid phase. The formulations will generally have from about 10 2 to about 10 4 cells/mg. These formulations will be administered at about 50 mg (liquid or dry) to 1 kg or more per hectare. The formulations can be applied to the environment of the lepidopteran, e.g., soil, by spraying, dusting, sprinkling, or the like. Mutants. Mutants of the novel isolates of the invention can be made by procedures well known in the art. For example, an asporogenous mutant can be obtained through ethylmethane sulfonate (EMS) mutagenesis of a novel isolate. The mutants can be made using ultraviolet light and nitrosoguanidine by procedures well known in the art. A smaller percentage of the asporogenous mutants will remain intact and not lyse for extended fermentation periods; these strains are designated lysis minus (-). Lysis minus strains can be identified by screening asporogenous mutants in shake flask media and selecting those mutants that are still intact and contain toxin crystals at the end of the fermentation. Lysis minus strains are suitable for a cell fixation process that will yield a protected, encapsulated toxin protein. To prepare a phage resistant variant of said asporogenous mutant, an aliquot of the phage lysate is spread onto nutrient agar and allowed to dry. An aliquot of the phage sensitive bacterial strain is then plated directly over the dried lysate and allowed to dry. The plates are incubated at 30°C. The plates are incubated for 2 days and, at that time, numerous colonies could be seen growing on the agar. Some of these colonies are picked and subcultured onto nutrient agar plates. These apparent resistant cultures are tested for resistance by cross streaking with the phage lysate. A line of the phage lysate is streaked on the plate and allowed to dry. The presumptive resistant cultures are then streaked across the phage line. Resistant bacterial cultures show no lysis anywhere in the streak across the phage line after overnight incubation at 30°C. The resistance to phage is then reconfirmed by plating a lawn of the resistant culture onto a nutrient agar plate. The sensitive strain is also plated in the same manner to serve as the positive control. After drying, a drop of the phage lysate is plated in the center of the plate and allowed to dry. Resistant cultures showed no lysis in the area where the phage lysate has been placed after incubation at 30°C for 24 hours. Following are examples which illustrate procedures, including the best mode, for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted. Example 1 - Culturine of the B.t Isolates of the Invention A subculture of a novel B.t isolate, or mutants thereof, can be used to inoculate the following medium, a peptone, glucose, salts medium. Bacto Peptone 7.5 g/1 Glucose 1.0 g1 KH 2 P0 4 3.4 g/1 K 2 HP0 4 4.35 g/1 Salt Solution 5.0 ml l CaCl 2 Solution 5.0 ml/l Salts Solution (100 ml) MgS0 4 -7H 2 0 2.46 g MnS0 4 H 2 0 0.04 g ZnS0 4 -7H 2 0 0.28 g FeS0 4 -7H 2 0 0.40 g CaCl 2 Solution (100 ml) CaCl 2 -2H 2 0 3.66 g pH 7.2 The salts solution and CaCl 2 solution are filter-sterilized and added to the autoclaved and cooked broth at the time of inoculation. Flasks are incubated at 30°C on a rotary shaker at 200 rpm for 64 hr. The above procedure can be readily scaled up to large fermentors by procedures well known in the art. The B.t spores and/or crystals, obtained in the above fermentation, can be isolated by procedures well known in the art. A frequently-used procedure is to subjert the harvested fermentation broth to separation techniques, e.g., centrifugation. Example 2 - Activity of B.t. Isolates Against Lepidopterans The following strains have been tested for anti-lepidopteran activity with the following results: Table 6. Bioassay results % Mortality Strain Trichoplusia ni Spodoptera eήgua PS81T1 96, 8 PS53C2 100, 100 PS31F4 100, 100 PS86V1 100 PS86I2 100, 92 PS73E 100, 100 PS81K 100, 100 PS83E2 100, 100 PS81E 100, 92 PS81Z3 100 PS53B5 100 PS83R 100 PS53B2 100 PS83N2 100 PS81B5 100, 100 PS86W1 100 PS91C2 100, 100 PS81A2 100, 100 Spodoptera exieua bioassay procedure. B.t cultures were harvested and resuspended in sterile deionized water. Fixed volumes of each culture were incorporated into USDA Insert Diet (Technical Bulletin 1528, U.S. Department of Agriculture, 1976). Twenty-four neonate S. eήgua were exposed to the diet for 6 days. Mortality readings were taken at this time. Trichoplusia ni bioassay procedure. B.t. cultures were harvested and resuspended in sterile deionized water. Fixed volumes of each culture were top loaded onto USDA Insect Diet. Trays were infested with neonate T. ni. After 6 days mortality was determined. Example 3 - Characterization of Toxin Genes by RFLP Analysis Total cellular DNA was prepared from Bacillus thuringiensis (B.t) cells grown to an optical density, at 600 nm, of 1.0. The cells were recovered by centrifugation, and protoplasts were prepared in TES buffer (30 mM Tris-HCl, 10 mM EDTA, 50 mM NaCl, pH = 8.0) containing 20% sucrose and 50 mg/ml lysozyme. The protoplasts were lysed by addition of SDS to a final concentration of 4%. The cellular material was precipitated overnight at 4°C in 100 mM (final concentration) neutral potassium chloride. The supernate was extracted twice with phenol/chloroform (1:1). The DNA was precipitated with ethanol and purified by isopycnic banding on a cesium chloride-ethidium bromide gradienL Total cellular DNA isolated from B.t. cells was digested with a restriction endonuclease and separated by electrophoresis on a 0.8% (w v) agarose-TAE (50 mM Tris-HCl, 20 mM NaOAc, 2.5 mM EDTA, pH = 8.0) buffered gel. A Southern blot of the gel was hybridized with the [ 32 P]- radiolabeled oligonucleotide probe, ATGATTCATGCGGCAGATA (SEQ ID NO. 5), and then washed to remove unbound radioartivity. The blot was exposed to KODAK X-OMAT™ film using standard autoradiography techniques. The results are an array of hybridizing bands (fingerprint) which correspond to toxin genes or toxin gene fragments. This type of characterization is known as Restriction Fragment Length Polymorphism (RFLP) analysis which classifies each isolate by a distinct DNA fingerprint. Table 7. DNA fingerprints for B.t. isolates of the subject invention Isolate Hybridizing Hiwdlll Fragments (Kb) PS81T1 1.13, 3.0, 9.4 PS53C2 1.052, 5.8, 6.6 PS31F4 5.5, 8.0 PS86V1 5.5, 6.0, 6.6 PS86I2 5.0, 6.6, 7.5, 12 PS73E 1.052, 1.13, 3.0, 8.5 PS81K 3.2, 7.5, 9.4, 13 PS83E2 3.2, 8.5, 12 PS81E 1.13, 3.2, 9.4 PS81Z3 1.13, 3.0, 8.5 PS53B5 1.13, 3.0, 7.5 PS83R 1.13, 3.0, 8.5, 12 PS53B2 1.052, 1.13, 3.0, 7.5 PS83N2 5.5 PS81B5 8.0, 13 PS86W1 5.5, 6.6 PS91C2 1.13, 3.0, 6.0, 7.5, 8.5 PS81A2 13, 16 Table 8. Hybridizing Hϊndlll fragments of B.t. isolates of the subject invention Isolate Novel Hybridizing H dIII Fragments (~Kb) PS91C2 3.0, 6.0, 7.5 PS83E2 3.2 PS86I2 5.0 PS31F4 5.5, 8.0 PS53C2 5.8 PS81T1 9.4 Example 4 - Molecular Cloning and Expression of a Novel CrylF Toxin Gene from Bacillus thuringiensis Strain PS91C2 Total cellular DNA was prepared from Bacillus thuringiensis (B.t.) cells grown to an optical density, at 600 nm, of 1.0. Cells were pelleted by centrifugation and resuspended in protoplast buffer (20 mg/ml lysozyme in 0.3 M sucrose, 25 mM Tris-Cl [pH 8.0], 25 mM EDTA). After incubation at 37°C for 1 hour, protoplasts were lysed by two cycles of freezing and thawing. Nine volumes of a solution of 0.1 M NaCl, 0.1% SDS, 0.1 M Tris-Cl were added to complete lysis. The cleared lysate was extracted twice with phenolxhloroform (1:1). Nucleic acids were precipitated with two volumes of ethanol and pelleted by centrifugation. The pellet was resuspended in TE buffer and RNase was added to a final concentration of 50 μg/ml. After incubation at 37°C for 1 hour, the solution was extracted once each with pheno chloroform (1:1) and TE-saturated chloroform. DNA was precipitated from the aqueous phase by the addition of one-tenth volume of 3 M NaOAc and two volumes of ethanol. DNA was pelleted by centrifugation, washed with 70% ethanol, dried, and resuspended in TE buffer. A 1.58 kbp fragment of the novel 130 kDa toxin gene was obtained by polymerase chain reaction (PCR) amplification from PS91C2 cellular DNA using the following primers: forward 5'-GAGTGGGAAG CAGATCTTAA TAATGCACAA TTAAGG-3' (SEQ ID NO. 6) and reverse 5'-ATAC(C or T)CGATCGATATGATA(G or A)TCCGT-3' (SEQ ID NO. 7). This DNA fragment was cloned into pBluescript S K (Stratagene, La Jolla, CA) and the DNA sequence determined by dideoxynucleotide sequencing methodology (Sanger et al [1977] Proc. NatL Acad. ScL USA 74:5463-5467) using Sequenase (U.S. Biochemicals, Cleveland, OH). DNA sequences unique to the CrylF gene were identified by computer comparison with other Cryl genes. An oligonucleotide probe with the following sequence was synthesized: 5 ' - CCCAATGTGAATGTACTTTGCGC-3' (SEQ ID NO. 8). This probe was radiolabeled with 32 P and used in standard hybridizations of Southern blots of PS91C2 total cellular DNA Hybridizing bands included an approximately 7.5 kbp Hόidlll fragment. A gene library was constructed from PS91C2 DNA partially digested with Ndeϊl. Partial restriction digests were fractionated by agarose gel electrophoresis. DNA fragments 9.3 to 23 kbp in size were excised from the gel, electroeluted from the gel slice, purified on an Elutip D ion exchange column (Schleicher and Schuell, Keene, NH), and recovered by ethanol precipitation. The Ndeϊl inserts were ligated into ftomHI-digested LambdaGem-11 (Promega, Madison, Wl). Recombinant phage were packaged and plated on E. coli KW251 cells. Plaques were screened by hybridization with each of the respective probes described above. Hybridizing phage were plaque- purified and used to infect liquid cultures of E. coli KW251 cells for isolation of DNA by standard procedures (Maniatis et al., supra). For subcloning the gene encoding the 130 kDa CrylF toxin, preparative amounts of phage DNA were digested with Sau3A and electrophoresed on agarose gel. The approximately 8 kbp band containing the toxin gene was excised from the gel, electroeluted from the gel slice, and purified by ion exchange chromatography as described above. The purified DNA insert was ligated into an ATioI-digested pHTBluell (an E. coli/B. thuringiensis shuttle vector comprised of pBluescript S/K (Stratagene) and the replication origin from a resident B.t plasmid (D. Lereclus et al [1989] FEMS MicrobioL Lett 60:211-218). The ligation mix was used to transform frozen, competent E. coli NM522 cells (ATCC 47000). 5-galactosidase transformants were screened by restriction digestion of alkaline lysate plasmid minipreps as above. The desired plasmid construct, pMYC2361, contains a toxin gene that is novel compared to other toxin genes containing inserticidal proteins. pMYC2361 was introduced into the acrystalliferous (Cry") B.t. host, CryB (A Aronson, Purdue University, West Lafayette, IN) by electroporation. Expression of the 130 kDa toxin was demonstrated by SDS-PAGE analysis. NaBr-purified crystals were prepared (Pfannenstiel, M.A et al. [1984] FEMS MicrobioL Lett 21:39) for determination of toxicity of the cloned gene product to Plutella xylostella by the screening method described in Example 3. The LC 50 for the CrylF toxin against P. xylostella was determined to be 5 μg toxin/ml diet. Example 5 - Insertion of Toxin Genes Into Plants One aspect of the subjert invention is the transformation of plants with genes encoding a lepidopteran toxin. The transformed plants are resistant to attack by lepidopterans. Genes encoding lepidopteran-active toxins, as disclosed herein, can be inserted into plant cells using a variety of techniques which are well known in the art. For example, a large number of cloning vectors comprising a replication system in E. coli and a marker that permits selection of the transformed cells are available for preparation for the insertion of foreign genes into higher plants. The vectors comprise, for example, pBR322, pUC series, M13mp series, pACYC184, etc. Accordingly, the sequence encoding the B.t toxin can be inserted into the vector at a suitable restriction site. The resulting plasmid is used for transformation into E. coli. The E. coli cells are cultivated in a suitable nutrient medium, then harvested and lysed. The plasmid is recovered. Sequence analysis, restriction analysis, electrophoresis, and other biochemical-molecular biological methods are generally carried out as methods of analysis. After each manipulation, the DNA sequence used can be cleaved and joined to the next DNA sequence. Each plasmid sequence can be cloned in the same or other plasmids. Depending on the method of inserting desired genes into the plant, other DNA sequences may be necessary. If, for example, the Tϊ or Ri plasmid is used for the transformation of the plant cell, then at least the right border, but often the right and the left border of the Ti or Ri plasmid T-DNA has to be joined as the flanking region of the genes to be inserted. The use of T-DNA for the transformation of plant cells has been intensively researched and sufficiently described in EP 0 120516; Hoekema (1985) In: The Binary Plant Vector System, Offset-durkkerij Kanters B.V., Alblasserdam, Chapter 5; Fraley et al, Crit. Rev. Plant ScL 4:1-46; and An et al (1985) EMBO J. 4:277-287. Once the inserted DNA has been integrated in the genome, it is relatively stable there and, as a rule, does not come out again. It normally contains a selection marker that confers on the transformed plant cells resistance to a biocide or an antibiotic, such as kanamycin, G 418, bleomycin, hygromycin, or chloramphenicol, inter alia. The individually employed marker should accordingly permit the selection of transformed cells rather than cells that do not contain the inserted DNA A large number of techniques are available for inserting DNA into a plant host cell. Those techniques include transformation with T-DNA using Agrobacterium tumefaciens or Agrobacterium rhizogenes as transformation agent, fusion, injection, or elertroporation as well as other possible methods. If agrobacteria are used for the transformation, the DNA to be inserted has to be cloned into special plasmids, namely either into an intermediate vector or into a binary vector. The intermediate vectors can be integrated into the Ti or Ri plasmid by homologous recombination owing to sequences that are homologous to sequences in the T-DNA The Ti or Ri plasmid also comprises the vir region necessary for the transfer of the T-DNA Intermediate vectors cannot replicate themselves in agrobacteria. The intermediate vector can be transferred into Agrobacterium tumefaciens by means of a helper plasmid (conjugation). Binary vectors can replicate themselves both in E. coli and in agrobacteria. They comprise a selection marker gene and a linker or polylinker which are framed by the right and left T-DNA border regions. They can be transformed directly into agrobacteria (Holsters et al [1978] MoL Gen. Genet. 163:181-187). The agrobacterium used as host cell is to comprise a plasmid carrying a vir region. The vir region is necessary for the transfer of the T-DNA into the plant cell. Additional T-DNA may be contained. The bacterium so transformed is used for the transformation of plant cells. Plant explants can advantageously be cultivated with Agrobacterium tumefaciens or Agrobacterium rhizogenes for the transfer of the DNA into the plant cell. Whole plants can then be regenerated from the infected plant material (for example, pieces of leaf, segments of stalk, roots, but also protoplasts or suspension-cultivated cells) in a suitable medium, which may contain antibiotics or biocides for selection. The plants so obtained can then be tested for the presence of the inserted DNA No special demands are made of the plasmids in the case of injection and elertroporation. It is possible to use ordinary plasmids, such as, for example, pUC derivatives. The transformed cells grow inside the plants in the usual manner. They can form germ cells and transmit the transformed trait(s) to progeny plants. Such plants can be grown in the normal manner and crossed with plants that have the same transformed hereditary factors or other hereditary factors. The resulting hybrid individuals have the corresponding phenotypic properties. Example 6 - Cloning of Novel B.t. Genes Into Insert Viruses A number of viruses are known to infect insects. These viruses include, for example, baculoviruses and entomopoxviruses. In one embodiment of the subjert invention, lepidopteran- active genes, as described herein, can be placed with the genome of the insect virus, thus enhancing the pathogenicity of the virus. Methods for construrting insert viruses which comprise B.t. toxin genes are well known and readily practiced by those skilled in the art. These procedures are described, for example, in Merryweather et al (Merryweather, AT., U. Weyer, M.P.G. Harris, M. Hirst, T. Booth, R.D. Possee [1990] J. Gen. ViroL 77:1535-1544) and Martens et al (Martens, J.W.M., G. Honee, D. Zuidema, J.W.M. van Lent, B. Visser, J.M. Vlak [1990] AppL Environmental MicrobioL 5d(9):2764-2770). It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT NAME(S): MYCOGEN CORPORATION STREET ADDRESS: 5501 Oberlin Drive CITY: San Diego STATE/PROVINCE: California COUNTRY: US POSTAL CODE/ZIP: 92121 PHONE NUMBER: (619) 453-8030 FAX NUMBER: (619) 453-6991 (ii) TITLE OF INVENTION: Protein Toxins Active Against Lepidopteran Pests (iii) NUMBER OF SEQUENCES: 27 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Saliwanchik & Saliwanchik (B) STREET: 2421 N.W. 41st Street, Suite A-1 (C) CITY: Gainesville (D) STATE: FL (E) COUNTRY: US (F) ZIP: 32606 (V) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (Vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (Vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 07/597,607 (B) FILING DATE: 15-OCT-90 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Saliwanchik, David R. (B) REGISTRATION NUMBER: 31,794 (C) REFERENCE/DOCKET NUMBER: MA50.C1 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (904)375-8100 (B) TELEFAX: (904)372-5800 (2) INFORMATION FOR SEQ ID Nθ:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3522 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double . (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANT -SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Bacillus thuringiensis (B) STRAIN: aizawai (C) INDIVIDUAL ISOLATE: PS81A2 ( ii) IMMEDIATE SOURCE: (A) LIBRARY: Lambdagem - 11 (tm) Library of August sick (B) CLONE: 81A2 (Xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:l: ATGGAGAATA ATATTGAAAA TCAATGCATA CCTTACAATT GTTTAAλTAA TCCTGAAGTA 60 GAGATATTAG GGATTGAAAG GTCAAATAGT AACGTAGCAG CAGAAATCGG CTTGGGGCTT 120 AGTCGTCTGC TCGTTTCCCG AATTCCACTA GGGGATTTTA TACTTGGCTT GTTTGATGTA 180 ATATGGGGGG CTATAGGTCC TTCACAATGG GATATATTTT TAGAGCAAAT TGAGCTATTG 240 ATCGGCCAAA GAATAGAGGA ATTCGCTAGG AATCAGGCAA TTTCTAGATT ACAAGGGCTA 300 AGCAATCTTT ACCGAATTTA CACAAATGCT TTTAAAAACT GGGAAGTAGA TCCTACTAAT 360 CCAGCATTAA GAGAAGAGAT GCGTATTCAA TTTAATGACA TGAACAGTGC TCTTACAACA 420 GCTATTCCTC TTTTTTCAGT TCAAGGTTAT GAAATTCCTC TTTTATCAGT ATATGTTCAA 480 GCTGCAAATT TACATTTATC GGTTTTGAGA GATGTTTCAG TGTTTGGACA ACGTTGGGGA 540 TTTGATGTAG CAACAATCAA TAGTCGTTAT AATGATTTAA CTAGGCTTAT TGGCGAATAT 600 ACTGATTATG CTGTACGTTG GTATAATACG GGGTTAAATC GTTTACCACG TAATGAAGGG 660 GTACGAGGAT GGGCAAGATT TAATAGGTTT AGAAGAGAGT TAACAATATC AGTATTAGAT 720 ATTATTTCTT TTTTCCAAAA TTACGATTCT AGATTATATC CAATTCCGAC AATCTATCAA 780 TTAACGCGGG AAGTATATAC AGATCCGGTA ATTAATATAA CTGATTATAG AGTTACCCCA 840 AGTTTCGAGA GTATTGAAAA TTCAGCTATT AGAAGTCCCC ATCTTATGGA TTTCTTAAAT 900 AATATAATTA TTGACACTGA TTTAATTAGA GGCGTTCACT ATTGGGCGGG GCATCGTGTA 960 ACTTCTCATT TTACCGGTAG TTCGCAAGTG ATAAGCTCCC CTCAATACGG GATAACTGCA 1020 AACGCAGAAC CGAGTCGAAC TATTGCTCCT AGCACTTTTC CAGGTCTTAA TCTATTTTAT 1080 AGAACACTAT CAGACCCTTT CTTCCGAAGA TCCGATAATA TTATGCCAAC ATTAGGAATA 1140 AATGTAGTGC AGGGGGTAGG ATTCATTCAA CCAAATAATG GTGAAGTTCT ATATAGAAGG 1200 AGAGGAACAG TAGATTCTCT TGATGAGTTG CCAATTGACG GTGAGAATTC ATTAGTTGGA 1260 TATAGTCATA GATTAAGTCA CGTTACATTA ACCAGGTCGT TATATAATAC TAATATAACT 1320 AGCTTGCCAA CATTTGTTTG GACACATCAC AGTGCTACTG ATCGAAATAT AATCTATCCG 1380 GATGTAATTA CACAAATACC ATTGGTAAAA TCATTCTCCC TTACTTCAGG TACCTCTGTA 1440 GTCAGAGGCC CAGGATTTAC AGGAGGGGAT ATCATCCGAA CTAACGTTAA TGGTAATGTA 1500 CTAAGTATGA GTCTTAATTT TAGTAATACA TCATTACAGC GGTATCGCGT GAGAGTTCGT 1560 TATGCTGCTT CTCAAACAA GGTCATGAGA GTAAATGTTG GAGGGAGTAC TACTTTTGAT 1620 CAAGGATTCC CTAGTACTAT GAGTGCAAAT GGGTCTTTGA CATCTCAATC ATTTAGATTT 1680 GCAGAATTTC CTGTAGGCAT TAGTACATCT GGCAGTCAAA CTGCTGGAAT AAGTATAAGT 1740 AATAATCCAG GTAGACAAAC GTTTCACTTA GATAGAATTG AATTTATCCC AGTTGATGCA 1800 ACATTTGAAG CAGAATATGA TTTAGAAAGA GCACAAAAGG CGGTGAATTC GCTGTTTACT 1860 TCTTCCAATC AAATCGAGTT AAAAACAGAT GTGACGGATT ATCATATTGA TCAAGTATCC 1920 AATTTAGTAG ATTGTTTATC CGATGAATTT TGTCTGGATG AAAAGCGAGA ATTGTCCGAG 1980 AAAGTCAAAC ATGCGAAGCG ACTCAGTGAT GAGCGGAATT TACTTCAAGA TCCAAACTTC 2040 AGAGGGATCA ATAGGCAACC AGACCGTGGC TGGAGAGGAA GTACGGATAT TACCATCCAA 2100 GGAGGAGATG ACGTATTCAA AGAGAATTAC GTCACACTAC CAGGTACCTT TGATGAGTGC 2160 TATCCAACGT ATTTGTATCA AAAAATAGAT GAGTCGAAAT TAAAAGCCTA TAACCGTTAC 2220 CAATTAAGAG GGTATATCGA AGATAGTCAA GACTTAGAAA TCTATTTAAT TCGCTACAAT 2280 GCAAAACACG AAACAGTAAA TGTACCAGGT ACGGGTTCCT TATGGCCGCT TTCAGTCGAA 2340 AGTCCAATTG GAAGGTGTGG AGAACCGAAT CGGTGTGTGC CACACCTTGA ATGGAATCCT 2400 GATTTAGATT GTTCCTGCAG AGACGGGGAA AAATGTGCAC ATCATTCCCA TCATTTCTCC 2460 TTGGACATTG ATGTTGGATG CACAGACTTG CAAGAGGATC TAGGCGTGTG GGTTGTATTC 2520 AAGATTAAGA CGCAGGAAGG TTATGCAAGA TTAGGAAATC TGGAATTTAT CGAAGAGAAA 2580 CCATTAATTG GAGAAGCACT GTCTCGTGTG AAGAGAGCGG AAAAAAAATG GAGAGACAAA 26 0 CGGGAAAAAC TACAATTGGA AACAAAACGA GTATATACAG AGGCAAAAGA AGCTGTGGAT 2700 GCTTTATTCG TAGATTCTCA ATATGATAGA TTACAAGCAG ATACAAACAT TGGTATGATT 2760 CATGCGGCAG ATAGACTTGT TCATCAGATC CACGAGGCTT ATCTTCCAGA ACTACCTTTC 2820 ATTCCAGGAA TAAATGTGGT GATTTTTGAA GAATTAGAAA ACCGTATTTC TACTGCATTA 2880 TCCCTATATG ATGCGAGAAA TGTCATTAAA AATGGCGATT TCAATAATGG CTTATCATGC 2940 TGGAACGTGA AAGGGCATGT AGATGTAGTA GAACAAAACA ACCACCGTTC GGTCCTTGTT 3000 GTCCCGGAAT GGGAAGCAGA AGTGTCACAA ACAATTCGTG TCTGTCCGGG GCGTGGCTAT 3060 ATCCTCCGTG TTACAGCGTA CAAAGAGGGA TATGGAGAAG GTTGCGTAAC CATCCATGAG 3120 ATCGAGAACA ATACAGACGA ACTAAAATTT AAAAACTGTG AAGAAGAGGA AGTGTATCCA 3180 ACGGATACAG GAACGTGTAA TGATTATACT GCACACCAAG GTACAGCAGG ATCCACAGAT 3240 TCATGTAATT CCCGTAATAT CAGATATGAG GATGCATATG AAATGAATAC TACAGCATCT 3300 GTTAATTACA AACCGACTTA CGAAGAAGAA AGGTATACAG ATGTACAAGG AGATAATCAT 3360 TGTGAATATG ACAGAGGGTA TGTGAATTAT CGACCAGTAC CAGCTGGTTA TGTGACAAAA 3420 GAATTAGAGT ACTTCCCAGA AACCGATAAG GTATGGATTG AGATCGGAGA AACGGAAGGG 3480 AAGTTTATTG TAGACAATGT CGAATTACTC CTTATGGAGG AA 3522 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1174 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (iv) ANTI-SENSE: NO (Vi) ORIGINAL SOURCE: (A) ORGANISM: Bacillus thuringiensis (B) STRAIN: aizawai (C) INDIVIDUAL ISOLATE: PS81A2 (vii) IMMEDIATE SOURCE: (A) LIBRARY: Lambdagem - 11 (t ) Library of August Sick (B) CLONE: 81A2 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Glu Asn Asn lie Glu Asn Gin Cys ie Pro Tyr Asn Cys Leu Asn 1 5 10 15 Asn Pro Glu Val Glu lie Leu Gly lie Glu Arg Ser Asn Ser Asn Val 20 25 30 Ala Ala Glu lie Gly Leu Gly Leu Ser Arg Leu Leu Val Ser Arg ie 35 40 45 Pro Leu Gly Asp Phe ie Leu Gly Leu Phe Asp Val lie Trp Gly Ala 50 55 60 lie Gly Pro Ser Gin Trp Asp ie Phe Leu Glu Gin lie Glu Leu Leu 65 70 75 80 ie Gly Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala He Ser Arg 85 90 95 Leu Gin Gly Leu Ser Asn Leu Tyr Arg He Tyr Thr Asn Ala Phe Lys 100 105 110 Asn Trp Glu Val Asp Pro Thr Asn Pro Ala Leu Arg Glu Glu Met Arg 115 120 125 He Gin Phe Asn Asp Met Asn ser Ala Leu Thr Thr Ala He Pro Leu 130 135 140 Phe Ser Val Gin Gly Tyr Glu He Pro Leu Leu Ser Val Tyr Val Gin 145 150 155 160 Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser Val Phe Gly 165 170 175 Gin Arg Trp Gly Phe Asp Val Ala Thr He Asn Ser Arg Tyr Asn Asp 180 185 190 Leu Thr Arg Leu He Gly Glu Tyr Thr Asp Tyr Ala Val Arg Trp Tyr 195 200 205 Asn Thr Gly Leu Asn Arg Leu Pro Arg Asn Glu Gly Val Arg Gly Trp 210 215 220 Ala Arg Phe Asn Arg Phe Arg Arg Glu Leu Thr He Ser Val Leu Asp 225 230 235 240 He He ser Phe Phe Gin Asn Tyr Asp Ser Arg Leu Tyr Pro He Pro 245 250 255 Thr He Tyr Gin Leu Thr Arg Glu Val Tyr Thr Asp Pro Val He Asn 260 265 270 He Thr Asp Tyr Arg Val Thr Pro Ser Phe Glu Ser He Glu Asn Ser 275 280 285 Ala He Arg Ser Pro His Leu Met Asp Phe Leu Asn Asn He He He 290 295 300 Asp Thr Asp Leu He Arg Gly Val His Tyr Trp Ala Gly His Arg Val 305 310 315 320 Thr Ser His Phe Thr Gly Ser Ser Gin Val He Ser Ser Pro Gin Tyr 325 330 335 Gly He Thr Ala Asn Ala Glu Pro Ser Arg Thr He Ala Pro Ser Thr 340 345 350 Phe Pro Gly Leu Asn Leu Phe Tyr Arg Thr Leu Ser Asp Pro Phe Phe 355 360 365 Arg Arg Ser Asp Asn He Met Pro Thr Leu Gly He Asn Val Val Gin 370 375 380 Gly Val Gly Phe He Gin Pro Asn Asn Gly Glu Val Leu Tyr Arg Arg 385 390 395 400 Arg Gly Thr Val Asp ser Leu Asp Glu Leu Pro He Asp Gly Glu Asn 405 410 415 Ser Leu Val Gly Tyr Ser His Arg Leu Ser His Val Thr Leu Thr Arg 420 425 430 Ser Leu Tyr Asn Thr Asn He Thr Ser Leu Pro Thr Phe Val Trp Thr 435 440 445 His His Ser Ala Thr Asp Arg Asn He He Tyr Pro Asp Val He Thr 450 455 460 Gin He Pro Leu Val Lys Ser Phe Ser Leu Thr Ser Gly Thr Ser Val 465 470 475 480 Val Arg Gly Pro Gly Phe Thr Gly Gly Asp He He Arg Thr Asn Val 485 490 495 Asn Gly Asn val Leu Ser Met Ser Leu Asn Phe Ser Asn Thr Ser Leu 500 505 510 Gin Arg Tyr Arg Val Arg Val Arg Tyr Ala Ala Ser Gin Thr Met Val 515 520 525 Met Arg Val Asn Val Gly Gly Ser Thr Thr Phe Asp Gin Gly Phe Pro 530 535 540 Ser Thr Met Ser Ala Asn Gly Ser Leu Thr Ser Gin Ser Phe Arg Phe 545 550 555 560 Ala Glu Phe Pro Val Gly He Ser Thr Ser Gly ser Gin Thr Ala Gly 565 570 575 He Ser He Ser Asn Asn Pro Gly Arg Gin Thr Phe His Leu Asp Arg 580 585 590 He Glu Phe ie Pro Val Asp Ala Thr Phe Glu Ala Glu Tyr Asp Leu 595 600 605 Glu Arg Ala Gin Lys Ala Val Asn ser Leu Phe Thr Ser Ser Asn Gin 610 615 620 He Glu Leu Lys Thr Asp Val Thr Asp Tyr His He Asp Gin Val Ser 625 630 635 640 Asn Leu Val Asp cys Leu Ser Asp Glu Phe Cys Leu Asp Glu Lys Arg 645 650 655 Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg Leu Ser Asp Glu Arg 660 665 670 Asn Leu Leu Gin Asp Pro Asn Phe Arg Gly He Asn Arg Gin Pro Asp 675 680 685 Arg Gly Trp Arg Gly Ser Thr Asp lie Thr He Gin Gly Gly Asp Asp 690 695 700 Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Phe Asp Glu Cys 705 710 715 720 Tyr Pro Thr Tyr Leu Tyr Gin Lys He Asp Glu Ser Lys Leu Lys Ala 725 730 735 Tyr Asn Arg Tyr Gin Leu Arg Gly Tyr He Glu Asp Ser Gin Asp Leu 740 745 750 Glu He Tyr Leu He Arg Tyr Asn Ala Lys His Glu Thr Val Asn Val 755 760 765 Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Val Glu Ser Pro He Gly 770 775 780 Arg Cys Gly Glu Pro Asn Arg Cys Val Pro His Leu Glu Trp Asn Pro 785 790 795 800 Asp Leu Asp cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His His Ser 805 810 815 His His Phe Ser Leu Asp He Asp Val Gly Cys Thr Asp Leu Gin Glu 820 825 830 Asp Leu Gly Val Trp Val Val Phe Lys He Lys Thr Gin Glu Gly Tyr 835 840 845 Ala Arg Leu Gly Asn Leu Glu Phe He Glu Glu Lys Pro Leu He Gly 850 855 860 Glu Ala Leu Ser Arg Val Lys Arg Ala Glu Lys Lys Trp Arg Asp Lys 865 870 875 880 Arg Glu Lys Leu Gin Leu Glu Thr Lys Arg Val Tyr Thr Glu Ala Lys 885 890 895 Glu Ala Val Asp Ala Leu Phe Val Asp Ser Gin Tyr Asp Arg Leu Gin 900 905 910 Ala Asp Thr Asn He Gly Met He His Ala Ala Asp Arg Leu Val His 915 920 925 Gin He His Glu Ala Tyr Leu Pro Glu Leu Pro Phe He Pro Gly He 930 935 940 Asn Val Val He Phe Glu Glu Leu Glu Asn Arg He Ser Thr Ala Leu 945 950 955 960 ser Leu Tyr Asp Ala Arg Asn Val He Lys Asn Gly Asp Phe Asn Asn 965 970 975 Gly Leu Ser Cys Trp Asn Val Lys Gly His Val Asp Val Val Glu Gin 980 985 990 Asn Asn His Arg ser Val Leu Val Val Pro Glu Trp Glu Ala Glu Val 995 1000 1005 Ser Gin Thr He Arg Val Cys Pro Gly Arg Gly Tyr He Leu Arg Val 1010 1015 1020 Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr He His Glu 1025 1030 1035 1040 He Glu Asn Asn Thr Asp Glu Leu Lys Phe Lys Asn Cys Glu Glu Glu 1045 1050 1055 Glu Val Tyr Pro Thr Asp Thr Gly Thr Cys Asn Asp Tyr Thr Ala His 1060 1065 1070 Gin Gly Thr Ala Gly Ser Thr Asp Ser Cys Asn Ser Arg Asn lie Arg 1075 1080 1085 Tyr Glu Asp Ala Tyr Glu Met Asn Thr Thr Ala ser Val Asn Tyr Lys 1090 1095 1100 Pro Thr Tyr Glu Glu Glu Arg Tyr Thr Asp Val Gin Gly Asp Asn His 1105 1110 1115 1120 Cys Glu Tyr Asp Arg Gly Tyr Val Asn Tyr Arg Pro Val Pro Ala Gly 1125 1130 1135 Tyr Val Thr Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val Trp 1140 1145 1150 He Glu He Gly Glu Thr Glu Gly Lys Phe He Val Asp Asn Val Glu 1155 1160 1165 Leu Leu Leu Met Glu Glu 1170 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3504 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (Vi) ORIGINAL SOURCE: (A) ORGANISM: Bacillus thuringiensis (B) STRAIN: Morrissoni (C) INDIVIDUAL ISOLATE: PS91C2 (vii) IMMEDIATE SOURCE: (A) LIBRARY: LambdaGem (TM) - 11 Library of Teresa Thompson (B) CLONE: 91C2 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: ATGAAGAATA ACATTCAAAA TCAATGCGTA CCTTACAATT GTTTAAGTAA TCCTGAAGTA 60 GAAATATTAA GTGAAGAAAG AAGTACTGGC AGATTACCGT TAGATATATC CTTGTCGCTT 120 ACACGTTTCC TTTTGAGTGA ATTTGTTCCA GGTGTGGGAG TTGCGTTTGG ATTATTTGAT 180 TTAATATGGG GTTTTATAAC TCCTTCTGAA TGGAGTTTAT TTCTTTTACA GATTGAACAA 2 0 CTGATTGAAC AAAGAATTGA AACATTGGAA AGGAACCGGG CAATTACTAC ATTACGAGGG 300 TTAGCGGATA GCTATGAAGT TTACCTTGAG GCACTAAGAG AGTGGGAAGA AAATCCTAAT 360 AATGCACAAT TAAGGGAAGA TGTGCGTATT CGATTTGCTA ATACAGACGA CGCTTTAATA 420 ACAGCAATAA ATAATTTTAC ACTTACAAGT TTTGAAATCC CTCTTTTATC GGTCTATGTT 480 CAAGCGGCGA ATCTACATTT ATCACTATTA AGAGATGCTG TATCGTTTGG GCAGGGTTGG 540 GGGCTGGATA TAGCTACTGT TAATAATCAT TATAATAGAT TAATAAATCT TATTCATAGA 600 TATACGGAAC ATTGTTTGGA CACATACAAT CAAGGATTAG AAAACTTAAG AGGTACTAAT 660 ACTCGACAAT GGTCAAGATT CAATCAGTTT AGGAGAGAGT TAACATTGAC TGTATTAGAT 720 ATCGTTGCTC TTTTTCCGAA CTACGATGCT AGAGCATATC CAATTCAAAC GTCATCCCAA 780 TTAACAAGGG AAATTTATAC AAGTTCAGTA ATTGAAGATT CTCCAGTTTC TGCTAATATA 840 CCTAATGGTT TTAATAGAGC GGAATTTGGA GTTAGACCGC CCCATCTTAT GGACTTTATG 900 AATTCTTTGT TTGTAACTGC AGAGACTGTT AGAAGTCAAA CTGTGTGGGG AGGACACTTA 960 GTTAGTTCAC GAAATACGGC TGGTAACCCT ATAAATTTCC CTATTTATGG GGTCTTCAAT 1020 CCTGGTGGCG CCATTTGGAT TGCAGATGAG GATCCACGTC CTTTTTATCG GACATTATCA 1080 GATCCTGTTT TTGTCCGAGG AGGATTTGGG GATCCTCATT ATGTACTTGG GCTTAGGGGA 1140 GTAGGATTTC AACAAACTGG TACGAACCAC ACCCGAACAT TTAGAAATAG TGGGACCATA 1200 GATTCTCTAG ATGAAATCCC ACCTCAGGAT AATAGTGGGG CACCTTGGAA TGATTATAGT 1260 CATGTATTAA ATCATGTTAC ATTTGTAAGG TGGCCTGGTG AGATTGCAGG AAGTGATTCA 1320 TGGAGAGCGC CAATGTTTTC TTGGACACAC CGTAGTGCAG ATCGTACAAA TATCATTAAT 1380 CCAAATATAA TTACACAAAT ACCTGCTGTA AAAGCACACA ATCTTCATTC GGGTTCTACG 1440 GTTGTTAGAG GACCCGGGTT TACAGGTGGT GATCTCTTAC GAAGAACGAA TACTGGTACA 1500 TTTGCAGATA TAAGAGTAAA TATTACTGGG CCATTATCTC AAAGATATCG TGTAAGAATT 1560 CGCTATGCTT CTACGACAGA TTTACAATTT TTCACGAGAA TCAATGGAAC TTCTGTAAAT 1620 CAAGGTAATT TCCAAAGAAC TATGAATAGA GGGGATAATT TAGAATCTGG AAACTTTAGG 1680 ACTGCAGGAT TTAGTACGCC TTTTAGTTTT TCAAATGCGC AAAGTACATT CACATTGGGT 1740 ACTCAGGCTT TTTCAAATCA GGAAGTTTAT ATAGATCGAA TTGAATTTGT CCCGGCAGAA 1800 GTAACATTCG AGGCAGAATC TGATTTAGAA AGAGCGCAAA AGGCGGTGAA TGCCCTGTTT 1860 ACTTCTACAA GCCAACTAGG GCTAAAAACA AATGTAACGG GTTACCATAT TGATCAAGTG 1920 TCCAATTTAG TTGCGTGTTT ATCGGATGAA TTTTGTCTGG ATGAAAAGAG AGAATTGTCC 1980 GAGAAAGTTA AACATGCGAA GCGACTCAGT GATAAGCGGA ATTTACTTCA AGATCCAAAC 2040 TTCAGAGGGA TCAATAGGCA ACCAGACCAT GGCTGGAGAG GAAGTACGGA TATTACTATC 2100 CAAGGAGGAG ATGACGTATT CAAAGAGAAT TACGTTACGC TACCGGGTAC TTTTGATGAG 2160 TGCTATCCAA CGTATTTATA TCAAAAAATA GATGAGTCGA AATTAAAAGC CTATACCCGT 2220 TATCAATTAA GAGGGTATAT CGAAGATAGT CAAGACTTAG AAATCTATTT AATTCGTTAC 2280 AATTCAAAAC ACGAAATAGT AAATGTACCA GGTACAGGGA GTTTATGGCC TCTTTCTGTA 2340 GAAAATCAAA TTGGACCTTG TGGAGAACCG AATCGATGCG CGCCACACCT TGAATGGAAT 2400 CCTGATTTAC ACTGTTCCTG CAGAGACGGG GAAAAATGTG TGCATCATTC TCATCATTTC 2460 TCTTTGGACA TTGATGTCGG ATGTACAGAT TTAAATGAGG ACCTAGGTGT ATGGTTGATA 2520 TTCAAGATTA AGACGCAAGA TGGCCACGCA AGACTAGGGA ATCTAGAGTT TCTCGAAGAG 2580 GAACCGTTAT TAGGCGAAGC GTTAGGACGT GTGAAGAGAG CGGAGAAGAA GTGGAGAGAC 2640 AAACGCGAGA AACTGCAGTT GGAAACAAAT ATTGTCTATA AAGAGGCAAA AGAATCTGTA 2700 GATGCTTTAT TTGTAAACTC TCAATATGAT AGATTACAAG CGGATACGAA CATCGCGATG 2760 ATTCATGCGG CAGATAAACG CGTTCATAGA ATCCGGGAAG CGTATCTGCC AGAGTTGTCT 2820 GTGATTCCAG GTGTCAATGC GGCCATTTTC GAAGAATTAG AGGGACGTAT TTTTACAGCG 2880 TATTCCTTAT ATGATGCGAG AAATGTTATT AAAAATGGCA ATTTCAATAA TGGCTTATTA 2940 TGCTGGAACG TGAAAGGGCA TGTAGATGTA GAAGAGCAAA ACAACCACCG TTCGGTCCTT 3000 GTTGTTCCGG AATGGGAAGC AGAAGTGTCA CAAGAAGTTC GTGTCTGTCC GGGTCGTGGC 3060 TATATCCTTC GTGTCACAGC GTACAAAGAG GGATATGGAG AAGGCTGCGT AACTATTCAT 3120 GAAGTCGATA ATAATACAGA CGAATTGAAG TTTAGCAACT GTGAGAAAGA ACAAGTATAT 3180 CCAGGTAATA CGGTAGCATG TAATGATTAT AATAAGAATC ACGGTGCGAA TGCATGTAGT 3240 TCTCGTAATC GTGGATATGA CGAATCTTAT GAAAGTAATT CTTCCATACC AGCTGATTAT 3300 GCACCGGTTT ATGAAGAAGA AGCGTATACA GATGGACAAA GAGGGAATCC TTGTGAATTT 3360 AACAGAGGGC ATACACCATT ACCAGCTGGT TATGTGACAG CAGAGTTAGA GTACTTCCCA 3420 GAAACGGATA CAGTATGGGT TGAGATTGGA GAAACGGAAG GAACATTTAT CGTGGACAGT 3480 GTGGAATTAC TCCTTATGGA GGAA 3504 ( 2 ) INFORMATION FOR SEQ ID NO : 4 : ( i ) SEQUENCE CHARACTERISTICS : ( A) LENGTH : 1168 amino acids ( B ) TYPE : amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: BACILLUS THURINGIENSIS (B) STRAIN: Morrissoni (C) INDIVIDUAL ISOLATE: PS91C2 (VU) IMMEDIATE SOURCE: (A) LIBRARY: LAMBDAGEM (TM) - 11 LIBRARY OF TERESA THOMPSON (B) CLONE: 91C2 ( i) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Lys Asn Asn He Gin Asn Gin cys Val Pro Tyr Asn cys Leu Ser 1 5 10 15 Asn Pro Glu Val Glu He Leu Ser Glu Glu Arg Ser Thr Gly Arg Leu 20 25 30 Pro Leu Asp lie Ser Leu Ser Leu Thr Arg Phe Leu Leu Ser Glu Phe 35 40 45 Val Pro Gly Val Gly Val Ala Phe Gly Leu Phe Asp Leu He Trp Gly 50 55 60 Phe He Thr Pro Ser Glu Trp Ser Leu Phe Leu Leu Gin He Glu Gin 65 70 75 80 Leu He Glu Gin Arg He Glu Thr Leu Glu Arg Asn Arg Ala He Thr 85 90 95 Thr Leu Arg Gly Leu Ala Asp Ser Tyr Glu Val Tyr Leu Glu Ala Leu 100 105 110 Arg Glu Trp Glu Glu Asn Pro Asn Asn Ala Gin Leu Arg Glu Asp Val 115 120 125 Arg He Arg Phe Ala Asn Thr Asp Asp Ala Leu He Thr Ala He Asn 130 135 140 Asn Phe Thr Leu Thr Ser Phe Glu He Pro Leu Leu ser Val Tyr Val 145 150 155 160 Gin Ala Ala Asn Leu His Leu Ser Leu Leu Arg Asp Ala Val Ser Phe 165 170 175 Gly Gin Gly Trp Gly Leu Asp He Ala Thr Val Asn Asn His Tyr Asn 180 185 190 Arg Leu He Asn Leu He His Arg Tyr Thr Glu His cys Leu Asp Thr 195 200 205 Tyr Asn Gin Gly Leu Glu Asn Leu Arg Gly Thr Asn Thr Arg Gin Trp 210 215 220 Ser Arg Phe Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val Leu Asp 225 230 235 240 He Val Ala Leu Phe Pro Asn Tyr Asp Ala Arg Ala Tyr Pro He Gin 245 250 255 Thr Ser Ser Gin Leu Thr Arg Glu He Tyr Thr Ser Ser Val He Glu 260 265 270 Asp Ser Pro Val Ser Ala Asn He Pro Asn Gly Phe Asn Arg Ala Glu 275 280 285 Phe Gly Val Arg Pro Pro His Leu Met Asp Phe Met Asn Ser Leu Phe 290 295 300 Val Thr Ala Glu Thr Val Arg Ser Gin Thr Val Trp Gly Gly His Leu 305 310 315 320 Val ser Ser Arg Asn Thr Ala Gly Asn Pro He Asn Phe Pro lie Tyr 325 330 335 Gly val Phe Asn Pro Gly Gly Ala He Trp He Ala Asp Glu Asp Pro 340 345 350 Arg Pro Phe Tyr Arg Thr Leu Ser Asp Pro Val phe val Arg Gly Gly 355 360 365 Phe Gly Asp Pro His Tyr Val Leu Gly Leu Arg Gly Val Gly Phe Gin 370 375 380 Gin Thr Gly Thr Asn His Thr Arg Thr Phe Arg Asn Ser Gly Thr He 385 390 395 400 Asp Ser Leu Asp Glu He Pro Pro Gin Asp Asn Ser Gly Ala Pro Trp 405 410 415 Asn Asp Tyr ser His Val Leu Asn His Val Thr Phe Val Arg Trp Pro 420 425 430 Gly Glu He Ala Gly Ser Asp Ser Trp Arg Ala Pro Met Phe Ser Trp 435 440 445 Thr His Arg Ser Ala Asp Arg Thr Asn He He Asn Pro Asn He He 450 455 460 Thr Gin He Pro Ala Val Lys Ala His Asn Leu His Ser Gly ser Thr 465 470 475 480 Val Val Arg Gly Pro Gly Phe Thr Gly Gly Asp Leu Leu Arg Arg Thr 485 490 495 Asn Thr Gly Thr Phe Ala Asp He Arg Val Asn He Thr Gly Pro Leu 500 505 510 ser Gin Arg Tyr Arg Val Arg He Arg Tyr Ala Ser Thr Thr Asp Leu 515 520 525 Gin Phe Phe Thr Arg He Asn Gly Thr Ser Val Asn Gin Gly Asn Phe 530 535 540 Gin Arg Thr Met Asn Arg Gly Asp Asn Leu Glu Ser Gly Asn Phe Arg 545 550 555 560 Thr Ala Gly Phe Ser Thr Pro Phe Ser Phe Ser Asn Ala Gin Ser Thr 565 570 575 Phe Thr Leu Gly Thr Gin Ala Phe Ser Asn Gin Glu Val Tyr He Asp 580 585 590 Arg He Glu Phe Val Pro Ala Glu Val Thr Phe Glu Ala Glu Ser Asp 595 600 605 Leu Glu Arg Ala Gin Lys Ala Val Asn Ala Leu Phe Thr Ser Thr Ser 610 615 620 Gin Leu Gly Leu Lys Thr Asn Val Thr Gly Tyr His He Asp Gin Val 625 630 635 640 ser Asn Leu Val Ala Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu Lys 645 650 655 Arg Glu Leu Ser Glu Lys Val Lys Bis Ala Lys Arg Leu Ser Asp Lys 660 665 670 Arg Asn Leu Leu Gin Asp Pro Asn Phe Arg Gly He Asn Arg Gin Pro 675 680 685 Asp His Gly Trp Arg Gly Ser Thr Asp He Thr He Gin Gly Gly Asp 690 695 700 Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Phe Asp Glu 705 710 715 720 Cys Tyr Pro Thr Tyr Leu Tyr Gin Lys He Asp Glu Ser Lys Leu Lys 725 730 735 Ala Tyr Thr Arg Tyr Gin Leu Arg Gly Tyr He Glu Asp ser Gin Asp 740 745 750 Leu Glu He Tyr Leu He Arg Tyr Asn Ser Lys His Glu He Val Asn 755 760 765 Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Val Glu Asn Gin He 770 775 780 Gly Pro Cys Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp Asn 785 790 795 800 Pro Asp Leu His Cys ser Cys Arg Asp Gly Glu Lys cys Val His His 805 810 815 Ser His His Phe Ser Leu Asp He Asp Val Gly Cys Thr Asp Leu Asn 820 825 830 Glu Asp Leu Gly Val Trp Leu He Phe Lys He Lys Thr Gin Asp Gly 835 840 845 His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu Glu Pro Leu Leu 850 855 860 Gly Glu Ala Leu Gly Arg Val Lys Arg Ala Glu Lys Lys Trp Arg Asp 865 870 875 880 Lys Arg Glu Lys Leu Gin Leu Glu Thr Asn He Val Tyr Lys Glu Ala 885 890 895 Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gin Tyr Asp Arg Leu 900 905 910 Gin Ala Asp Thr Asn He Ala Met He His Ala Ala Asp Lys Arg Val 915 920 925 His Arg He Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val He Pro Gly 930 935 940 Val Asn Ala Ala He Phe Glu Glu Leu Glu Gly Arg He Phe Thr Ala 945 950 955 960 Tyr Ser Leu Tyr Asp Ala Arg Asn Val He Lys Asn Gly Asn Phe Asn 965 970 975 Asn Gly Leu Leu Cys Trp Asn Val Lys Gly His Val Asp Val Glu Glu 980 985 990 Gin Asn Asn His Arg Ser Val Leu Val Val Pro Glu Trp Glu Ala Glu 995 1000 1005 Val Ser Gin Glu Val Arg Val Cys Pro Gly Arg Gly Tyr He Leu Arg 1010 1015 1020 Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr He His 1025 1030 1035 1040 Glu Val Asp Asn Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Glu Lys 1045 1050 1055 Glu Gin Val Tyr Pro Gly Asn Thr Val Ala Cys Asn Asp Tyr Asn Lys 1060 1065 1070 Asn His Gly Ala Asn Ala Cys Ser Ser Arg Asn Arg Gly Tyr Asp Glu 1075 1080 1085 Ser Tyr Glu Ser Asn Ser Ser He Pro Ala Asp Tyr Ala Pro Val Tyr 1090 1095 1100 Glu Glu Glu Ala Tyr Thr Asp Gly Gin Arg Gly Asn Pro Cys Glu Phe 1105 1110 1115 1120 Asn Arg Gly His Thr Pro Leu Pro Ala Gly Tyr Val Thr Ala Glu Leu 1125 1130 1135 Glu Tyr Phe Pro Glu Thr Asp Thr Val Trp Val Glu He Gly Glu Thr 1140 1145 1150 Glu Gly Thr Phe He Val Asp Ser Val Glu Leu Leu Leu Met Glu Glu 1155 1160 1165 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) ( i) SEQUENCE DESCRIPTION: SEQ ID NO:5: ATGATTCATG CGGCAGATA 19 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: GAGTGGGAAG CAGATCTTAA TAATGCACAA TTAAGG 36 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: ATACYCGATC GATATGATAR TCCGT 25 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: CCCAATGTGA ATGTACTTTG CGC 23 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Ser Thr Gly Arg Leu Pro Leu Asp 5 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: AGTACWGGMA GRTTACCRTT RGAY 24 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Glu Asp Ser Pro Val Ser Ala Asn 5 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: GARGATTCWC CAGTWTCWGC WAAT 24 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Asn Gly Phe Asn Arg Ala Glu Phe Gly val 5 10 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: AATGGWTTTA ATAGTGCTGA ATTTGGGAGT W 31 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Val Thr Ala Glu Thr Val Arg Ser Gin Thr 5 10 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: GTAACWGCAG ARACWGTWAG WAGTCAAACW 30 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Val Phe Asn Pro Gly Gly Ala He Trp He Ala Asp Glu 5 10 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: GTMTTYAATC CWGGWGGMGC MATWTGGATW GCWGATGARG AT 42 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: Val Arg Gly Gly Phe Gly 5 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: GTMMGAGGWG GWTTTGGR 18 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ( i) SEQUENCE DESCRIPTION: SEQ ID NO:21: Gly Thr Asn His Thr Arg Thr 5 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: GGWACRAAYC AYACMMGAAC W 21 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: Val Arg Trp Pro Gly Glu He 5 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: GTWMGATGGC CWGGWGARAT W 21 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: Ser Asp Ser Trp Arg Ala 5 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: AGTGATTCWT GGAGAGCW 18 (2) INFORMATION FOR SEQ ID NO:27: <i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1174 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: Met Xaa Asn Asn He Gin Asn Gin Cys Val Pro Tyr Asn Cys Leu Xaa 1 5 ' 10 15 Asn Pro Glu Val Glu lie Leu Xaa Glu Glu Arg Ser Thr Gly Arg Leu 20 25 30 96/05314 43 Pro Leu Asp He Ser Leu Ser Leu Thr Arg Phe Leu Leu Ser Glu Phe 35 40 45 Val Pro Gly Val Gly Val Ala Phe Gly Leu Phe Asp Leu He Trp Gly 50 55 60 Phe He Thr Pro Ser Xaa Trp Ser Leu Phe Leu Leu Gin He Glu Gin 65 70 75 80 Leu He Glu Gin Arg He Glu Thr Leu Glu Arg Asn Arg Ala He Thr 85 90 95 Thr Leu Arg Gly Leu Ala Asp Ser Tyr Glu Xaa Tyr Xaa Glu Ala Leu 100 105 110 Arg Glu Trp Glu Xaa Asn Pro Asn Asn Ala Gin Leu Arg Glu Asp Val 115 120 125 Arg He Arg Phe Ala Asn Thr Asp Asp Ala Leu He Thr Ala He Asn 130 135 140 Asn Phe Thr Leu Thr Ser Phe Glu He Pro Leu Leu Ser Val Tyr Val 145 150 155 160 Gin Ala Ala Asn Leu His Leu Ser Leu Leu Arg Asp Ala Val Ser Phe 165 170 175 Gly Gin Gly Trp Gly Leu Asp He Ala Thr Val Asn Asn His Tyr Asn 180 185 190 Arg Leu He Asn Leu He His Arg Tyr Thr Xaa His Cys Leu Asp Thr 195 200 205 Tyr Asn Gin Gly Leu Glu Asn Leu Arg Gly Thr Asn Thr Arg Gin Trp 210 215 220 Xaa Arg Phe Asn Gin Phe Arg Arg Xaa Leu Thr Leu Thr Val Leu Asp 225 230 235 240 He Val Ala Leu Phe Pro Asn Tyr Asp Xaa Arg Xaa Tyr Pro He Gin 245 250 255 Thr Ser Ser Gin Leu Thr Arg Glu He Tyr Thr Ser Ser Val He Glu 260 265 270 Asp Ser Pro val Ser Ala Asn He Pro Asn Gly Phe Asn Arg Ala Glu 275 280 285 Phe Gly Val Arg Pro Pro His Leu Met Asp Phe Met Asn Ser Leu Phe 290 295 300 Val Thr Ala Glu Thr Val Arg Ser Gin Thr Val Trp Gly Gly His Leu 305 310 315 320 Val Ser Ser Arg Asn Thr Ala Gly Asn Xaa He Asn Phe Pro Xaa Tyr 325 330 335 Gly Val Phe Asn Pro Gly Gly Ala He Trp He Ala Asp Glu Asp Pro 340 345 350 Arg Pro Phe Tyr Arg Thr Leu Ser Asp Pro Val Phe Val Arg Gly Gly 355 360 365 Phe Gly Xaa Pro His Tyr Val Leu Gly Leu Arg Gly Val Xaa Phe Gin 370 375 380 Gin Thr Gly Thr Asn His Thr Arg Thr Phe Arg Asn Ser Gly Thr He 385 390 395 400 Asp Ser Leu Asp Glu He Pro Pro Gin Asp Asn Ser Gly Ala Pro Trp 405 410 415 Asn Asp Tyr Ser His Val Leu Asn His Val Thr Phe Val Arg Trp Pro 420 425 430 Gly Glu He Xaa Gly Ser Asp Ser Trp Arg Ala Pro Met Phe Ser Trp 435 440 445 Thr His Arg Ser Ala Xaa Xaa Thr Asn Xaa He Xaa Pro Xaa Xaa He 450 455 460 Thr Gin He Pro Xaa Val Xaa Ala His Xaa Leu Xaa Ser Gly Xaa Thr 465 470 475 480 Val Val Arg Gly Pro Gly Phe Thr Gly Gly Asp Xaa Leu Arg Arg Thr 485 490 495 Xaa Xaa Gly Xaa Phe Ala Xaa Xaa Xaa Val Asn He Xaa Gly Xaa Leu 500 505 510 Xaa Gin Arg Tyr Arg Xaa Arg He Arg Tyr Ala Ser Thr Thr Xaa Leu 515 520 525 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly xaa Xaa Xaa Xaa Xaa Gly Xaa Phe 530 535 540 Xaa Xaa Thr Met Xaa Xaa Gly Asp Xaa Leu Xaa Xaa Xaa xaa Phe Xaa 545 550 555 560 Xaa Ala Xaa Xaa Xaa Thr Xaa Phe xaa Phe Xaa Xaa Xaa Gin Ser Xaa 565 570 575 Phe Thr Xaa Gly Xaa Xaa Xaa Phe Xaa Ser Xaa Xaa Glu Val Tyr He 580 585 590 Asp Xaa Xaa Glu Xaa Xaa Pro Xaa xaa Xaa Thr Phe Glu Ala Glu Xaa 595 600 605 Asp Xaa Glu Arg Ala Gin Xaa Ala Val Asn Ala Leu Phe Thr Ser Xaa 610 615 620 aa Gin Xaa Gly Xaa Xaa Thr Xaa Val Thr Xaa Tyr His He Asp Gin 625 630 635 640 Val Ser Asn Leu Val Xaa Cys Leu ser Asp Glu Phe Cys Leu Asp Glu 645 650 655 Xaa Arg Glu Leu Ser Glu Xaa Val His Xaa Ala Xaa Arg Leu Ser Asp 660 665 670 Xaa Arg Asn Leu Leu Gin Asp Pro Asn Phe Xaa Gly He Asn Arg Gin 675 680 685 Xaa Asp Xaa Gly Trp Arg Gly Ser Thr Asp He Thr He Gin Xaa Gly 690 695 700 Asp Asp Val Phe Xaa Glu Asn Tyr Val Thr Leu Pro Gly Thr Phe Asp 705 710 715 720 Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin Xaa He Asp Glu Ser Xaa Leu 725 730 735 Xaa Xaa Tyr Thr Arg Tyr Gin Leu Arg Gly Tyr lie Glu Asp Ser Gin 740 745 750 Asp Leu Glu He Tyr Leu He Arg Tyr Asn Xaa Xaa His Glu Pro Val 755 760 765 Asn Val Xaa Gly Thr Gly Ser Leu Trp Pro Leu ser Val xaa Xaa Xaa 770 775 780 He Xaa Xaa Cys Gly Glu Pro Asn Arg cys Ala Pro His Leu Glu Trp 785 790 795 800 Asn Pro Asp Leu Xaa cys Ser cys Arg Asp Gly Glu Xaa Cys Xaa His 805 810 815 His Ser His His Phe Ser Leu Asp He Asp Val Gly Cys Thr Asp Leu 820 825 830 Asn Glu Asp Leu Xaa Val Trp xaa He Phe Xaa lie Xaa Thr Gin Asp 835 840 845 Gly His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu Xaa Pro Leu 850 855 860 Xaa Gly Glu Ala Leu Xaa Arg val Xaa Arg Ala Glu Xaa Xaa Trp Arg 865 870 875 880 Asp xaa Arg Glu Xaa Leu Xaa Leu Glu Thr Asn lie Val Tyr Xaa Glu 885 890 895 Ala Xaa Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gin Tyr Asp Xaa 900 905 910 Leu Gin Ala Asp Thr Asn He Ala Met lie His Ala Ala Asp Xaa Arg 915 920 925 Val His Arg lie Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val He Pro 930 935 940 Gly Val Asn Xaa Xaa lie Phe Glu Glu Leu Xaa Gly Arg lie Phe Thr 945 950 955 960 Ala xaa Xaa Leu Tyr Asp Ala Arg Asn val He xaa Asn Gly Xaa Phe 965 970 975 Asn Asn Gly Leu Xaa Cys Trp Asn Val Xaa Gly His Val Asp Val Glu 980 985 990 Glu Gin Asn Asn His Arg Ser Val Leu Val Val Pro Glu Trp Glu Ala 995 1000 1005 Glu Val Ser Gin Glu Val Arg Val Cys Pro Gly Arg Gly Tyr He Leu 1010 1015 1020 Arg val Thr Ala Tyr Xaa Glu Gly Tyr Gly -Glu Gly Cys val Thr He 1025 1030 1035 1040 His Glu Xaa Xaa Asn Asn Thr Asp Glu Leu Xaa Phe Ser Asn Cys Xaa 1045 1050 1055 Xaa Glu Xaa Val Tyr Pro Xaa Asn Thr Val Xaa Cys Asn Asp Tyr Xaa 1060 1065 1070 Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Ala Xaa Xaa ser Arg Asn Arg Gly 1075 1080 1085 Tyr Asp Glu Xaa Tyr Xaa Ser Asn Ser ser Xaa Pro Ala Asp Tyr Ala 1090 1095 1100 Xaa Val Tyr Glu Glu Xaa Xaa Tyr Thr Asp Gly Xaa Arg Xaa Asn Pro 1105 1110 1115 1120 cys Glu Xaa Asn Arg Gly Xaa Xaa Xaa Xaa Thr Pro Leu Pro Ala Gly 1125 1130 1135 Tyr Val Thr Xaa Glu Leu Glu Tyr Phe Pro Glu Thr Asp Xaa Val Trp 1140 1145 1150 Xaa Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp Ser Val Glu 1155 1160 1165 Leu Leu Leu Met Glu Glu 1170

Claims: Claims 1. A process for controlling lepidopteran pests which comprises contacting said pests with a lepidopteran-controlling effective amount of Bacillus thuringiensis PS91C2, or spores, crystals, or toxins from said isolate, or mutants thereof which retain activity against lepidopteran pests. 2. The process, according to claim 1, wherein a substantially intact Bacillus thuringiensis isolate, or mutant thereof which retains artivity against lepidopteran pests, is treated to prolong the pesticidal activity when the substantially intact cell is applied to the environment of a target pest. 3. A composition of matter comprising Bacillus thuringiensis PS91C2, or a mutant thereof, or spores or crystals of said isolate, in association with an insecticide carrier. 4. A substantially pure toxin protein wherein said toxin has artivity against a lepidopteran pest and has at least one characteristic selected from the group consisting of: (a) the amino acid sequence of said toxin conforms to the Generic Formula shown in SEQ ID NO. 27; (b) the amino acid sequence of said toxin is at least 75% homologous with toxin 91C2; (c) the DNA which encodes said toxin hybridizes with DNA which encodes all or part of protein 91C2; (d) the DNA which encodes said toxin hybridizes with a probe selected from the group consisting of SEQ ID NO. 10, SEQ ID NO. 12, SEQ ED NO. 14, SEQ ED NO. 16, SEQ ED NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, and SEQ ED NO. 26, and DNA encoding SEQ ED NO. 9, SEQ ED NO. 11, SEQ ED NO. 13, SEQ ED NO. 15, SEQ ED NO. 17, SEQ ID NO. 19, SEQ ED NO. 21, SEQ ED NO. 23, and SEQ ED NO. 25; (e) said toxin is immunoreactive with an antibody which immunoreacts with toxin 91C2; and (f) the amino acid sequence of said toxin has an alignment value of at least about 450 with toxin 91C2. 5. The toxin, according to claim 4, wherein said toxin conforms to said Generic Formula shown in SEQ ED NO. 27. 6. The toxin, according to claim 4, wherein the amino acid sequence of said toxin has an alignment value of at least about 450 with toxin 91 C2. 7. The toxin, according to claim 4, wherein the DNA encoding said toxin hybridizes with DNA which encodes all or part of toxin 91C2. 8. The toxin, according to claim 4, wherein the DNA which encodes said toxin hybridizes with a probe selected from the group consisting of SEQ ED NO. 10, SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, and SEQ ID NO. 26, and DNA coding for SEQ ID NO. 9, SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 21, SEQ ID NO. 23, and SEQ ID NO. 25. 9. The toxin, according to claim 4, wherein said toxin is immunoreactive with an antibody which immunoreacts with protein 91 C2. 10. The toxin, according to claim 4, wherein said toxin has the amino acid sequence consisting essentially of the sequence shown in SEQ ID NO. 4. 11. An isolated polynucleotide encoding a Bacillus thuringiensis toxin as defined in claim 4. 12. An isolated polynucleotide, according to claim 11, wherein said polynucleotide comprises DNA which encodes an amino acid sequence shown in SEQ ID NO. 4. 13. The polynucleotide, according to claim 11, wherein said polynucleotide comprises a nucleotide sequence consisting essentially of the sequence shown in SEQ ID NO. 3. 14. A method for controlling lepidopteran pests, wherein said method comprises contacting said pests with a lepidopteran-controlling effective amount of a toxin as defined in claim 1. 15. A host transformed by a nucleotide sequence encoding a toxin as described in claim 4. 16. The transformed host, according to claim 15, wherein said host is transformed by a nucleotide sequence encoding a toxin protein having the amino acid sequence of SEQ ED NO. 4. 17. The transformed host, according to claim 15, wherein said host is transformed to express the nucleotide sequence of SEQ ID NO. 3. 18. A toxin encoded by a nucleotide sequence obtainable from Bacillus thuringiensis PS91C2, and variants thereof, wherein said toxin is active against lepidopteran pests.

Inventors: NARVA KENNETH E, PAYNE JEWEL, SCHNEPF H ERNEST, SCHWAB GEORGE E, SICK AUGUST J, NARVA, KENNETH, E., PAYNE, JEWEL, SCHNEPF, H., ERNEST, SCHWAB, GEORGE, E., SICK, AUGUST, J.
Applicants: MYCOGEN CORP, MYCOGEN CORPORATION
Application year: 1995
Main classification: C12N15
IPC codes: A01N63, C07K14, C12N1, C12N5, C12N15, C12P21, C12R1